ProCE Banner Activity

Promising New Agents for Patients With Relapsed/Refractory Myeloma

Clinical Thought
New approaches promise to transform care in multiple myeloma again. Read my thoughts on the most promising novel agents in clinical trial!

Released: October 30, 2019

Expiration: October 28, 2020

No longer available for credit.

Share

Faculty

Sarah A. Holstein

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

Celgene

Janssen administered by Scientific Affairs

Oncopeptides

Faculty Disclosure

Primary Author

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Sarah A. Holstein, MD, PhD, has disclosed that she has received consulting fees from Celgene, Genentech, GlaxoSmithKline, Oncopeptides, and Takeda.